Vaccine Related Immune Responses 2.0

Dear Colleagues,

The use of vaccination to prevent infectious diseases was described long before establishing the fundamental dogmas of the immune system. Most vaccines work by mimicking infections. Vaccines activate the immune system and generate memory T and B lymphocytes that "remember" the disease-causing agents. Upon encountering these pathogens later, the immune system will mount a rapid and robust immune response to antigens it has previously experienced, thereby preventing disease or reducing its severity. The initial response to a vaccine is similar to the primary response upon first exposure to a pathogen—that is, slow and limited. Subsequent doses of the vaccine boost the immune response, resulting in the production of long-lived antibodies and memory cells. For most vaccines, more than one dose is necessary to provide long-lasting protection.

Since the advent of recombinant DNA technology, vaccines have become the mainstay of protection against several infectious and non-infectious diseases. How a vaccine stimulates the immune system depends on many factors, such as the nature of the antigens, the route of administration, and the adjuvants present in the vaccines. The nature of the adjuvants is fundamental to determining the type, duration, and intensity of the primary response, and the characteristics of the resulting antigen-specific memory.

This Special Issue aims to collect recent research related to vaccine-related immune responses, including recent advances in mRNA vaccines. We hope to provide a broad overview of how different vaccines work and help readers to understand some new techniques and their utilization in vaccinology.

Dr. Abhisek Bhattacharya
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.